Dr Miyamoto speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy. He goes on to highlight that transcriptional profiling...
Original Article: Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy
NEXT ARTICLE